Results 41 to 50 of about 799,914 (365)
Frontiers in Endocrinology, 2016 We are developing an orally available small molecule, allosteric TSH receptor (TSHR) agonist for follow up diagnostics of patients with thyroid cancer.
Susanne Neumann +7 more
doaj +1 more source
Neuroreceptor Activation by Vibration-Assisted Tunneling [PDF]
Scientific Reports 5, Article number: 9990 Published 2015, 2015 G protein-coupled receptors (GPCRs) constitute a large family of receptor proteins that sense molecular signals on the exterior of a cell and activate signal transduction pathways within the cell. Modeling how an agonist activates such a receptor is fundamental for an understanding of a wide variety of physiological processes and it is of tremendous ...
arxiv +1 more source
Potential Adiponectin Receptor Response Modifier Therapeutics
Frontiers in Endocrinology, 2019 Many human diseases may benefit from adiponectin replacement therapy, but due to pharmacological disadvantages of the intact protein, druggable options focus on peptidic, and small molecule agonists of the adiponectin receptor.
Laszlo Otvos, Laszlo Otvos, Laszlo Otvos
doaj +1 more source
Target sites for chemical regulation of strigolactone signaling
Frontiers in Plant Science, 2014 Demands for plant growth regulators (chemicals that control plant growth) are increasing globally, especially in developing countries. Both positive and negative plant growth regulators are widely used to enhance crop production and to suppress unwanted ...
Hidemitsu eNakamura +3 more
doaj +1 more source
α1D-Adrenoceptors are responsible for the high sensitivity and the slow time-course of noradrenaline-mediated contraction in conductance arteries [PDF]
, 2013 The objective of this study was to determine whether the different time-course characteristics of α1-adrenoceptor-mediated contraction in arteries can be related to the subtypes involved.
Alexander +53 more
core +1 more source
Immune Checkpoints as Therapeutic Targets in Autoimmunity
Frontiers in Immunology, 2018 Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged—immune related adverse events.
Christopher Paluch +9 more
doaj +1 more source
Frontiers in Cellular Neuroscience, 2019 A paradigm shift has emerged in Parkinson’s disease (PD) highlighting the prominent role of CD4+ Tregs in pathogenesis and treatment. Bench to bedside research, conducted by others and our own laboratories, advanced a neuroprotective role for Tregs ...
R. Lee Mosley +8 more
doaj +1 more source
Down Regulation with Luteal GnRH Agonist Therapy in Euploid Embryo Transfers Does Not Impact Pregnancy Rates [PDF]
, 2020 Introduction : Gonadotropin-releasing hormone (GnRH) agonists have been used during assisted reproductive technology (ART) treatment for pituitary suppression and stimulation.
Bergin, MD, Keri +4 more
core +1 more source
Probing the role of the cation–π interaction in the binding sites of GPCRs using unnatural amino acids [PDF]
, 2009 We describe a general application of the nonsense suppression methodology for unnatural amino acid incorporation to probe drug–receptor interactions in functional G protein-coupled receptors (GPCRs), evaluating the binding sites of both the M2 muscarinic
Ballesteros +31 more
core +3 more sources
A covalently bound photoisomerizable agonist. Comparison with reversibly bound agonists at electrophorus electroplaques [PDF]
, 1980 After disulphide bonds are reduced with dithiothreitol, trans-3-(alpha-bromomethyl)-3’-[alpha-(trimethylammonium)methyl]azobenzene (trans-QBr) alkylates a sulfhydryl group on receptors.
Erlanger, Bernard F. +4 more
core +2 more sources